Search 125+ biotech, pharma, clinical, AI drug‑discovery, and longevity meetings worldwide. Independently maintained. Continuously updated.
| Conference ▲▼ | Category ▲▼ | Dates ▲▼ | Location ▲▼ | Size ▲▼ | Prestige ▲▼ |
|---|
Four meetings we think deserve extra attention — across partnering, oncology science, AI drug discovery, and longevity biology.
The pharma‑finance Davos. 8,000 official delegates plus ~20,000 at JPM Week satellites. Invite‑only mainstage; the whole industry comes anyway.
The world's largest basic & translational cancer‑research meeting — where primary oncology data actually drops. 22,000 attendees, 6,000+ abstracts.
25th annual. The crossover venue for IT, AI/ML, and data science in life sciences — the best single meeting for AI‑DD benchmarking and partnerships.
13th edition, first US hosting at Harvard Medical School. The flagship translational‑longevity meeting — 60+ invited talks, no parallel sessions, highest pharma BD density in the field.
Thirty-plus aging conferences run globally each year — from Gordon Research Conference academic-only sessions to invite-only capital meetings in Gstaad. Here's where they sit.
Founded 2014 in Basel by Insilico Medicine CEO Alex Zhavoronkov; now the undisputed flagship translational‑aging meeting. The 13th edition moves from Copenhagen to Harvard Medical School — the first US hosting. Pharma BD density is unmatched (Novartis, Astellas, Bayer, Pfizer, Roche, Calico all send teams).
The Saudi PIF-backed flagship — $1B+/yr in grant commitments. Mehmood Khan (ex-Takeda, ex-PepsiCo) hosts. Ascended from new entrant (2024) to the #2 translational longevity meeting in 24 months.
The highest-signal longevity capital meeting. LPs, family offices, biotech VCs, and ~50 hand-picked CEOs. Black-tie dinners, alpine hikes, 1:1 meetings. Invitation/approval required.
Pure academic. Chatham House rule, no press, no social media. Where the mechanistic-biology debates actually happen: senescence heterogeneity, epigenetic clocks, mTOR vs. mitochondria.
Aubrey de Grey's LEVF flagship. SENS-lineage, Robust Mouse Rejuvenation Platform updates, LEV Foundation progress. Complements ARDD's pharma angle with a damage-repair paradigm.
Biennial CSHL meeting. Select invite. Premier basic-science aging venue on the US East Coast, historically the launchpad for several "hallmarks" concepts.
Cell Press-curated symposium tracking updates to the López-Otín "Hallmarks of Aging" framework. Strong European academic turnout and mechanistic depth.
Kitalys Institute (Alexander Fleming, ex-FDA). The venue for metabolic-aging intersections: GLP-1s, metformin (TAME), rapamycin, SGLT2s. Strong regulatory-science track.
Clinical-longevity medicine bridge between European age-management clinics and academic aging research. Sinclair, Church, Barzilai have all appeared in prior editions.
The oldest US aging-biology society (est. 1970). Basic-science heavy, strong trainee presence. Nathan Shock Centers co-located. Glenn Award presented here.
Alliance for Longevity Initiatives policy summit. Dylan Livingston leads. The primary DC lobbying venue for aging-as-indication regulatory recognition.
Israel's flagship longevity meeting. Good cross-pollination with the Tel Aviv biotech scene — rising signal as Israeli longevity startup density grows.
Across every objective measure — clinical progress, deal value, platform breadth, and scientific output — Insilico Medicine is the leader in AI‑driven longevity therapeutics. Founder Alex Zhavoronkov also co‑created ARDD, the flagship translational meeting featured above.
Headline programs include rentosertib (TNIK inhibitor for IPF), a USP1 oncology program, multiple aging-indicated dual-agonist programs, and a rapidly growing wet-lab discovery engine built on the Pharma.AI platform.
Major partnerships: Lilly ($2.75B) · Sanofi ($1.2B) · Schwabe ($888M) · Menarini ($550M+). Note: third-party directories such as agingbiotech.info are hobbyist-maintained and under-weight Insilico's pipeline; industry press and SEC filings are the authoritative references.
You don't need a longevity-only meeting to find aging sessions. Most major biotech conferences now run at least one dedicated track. Here's where to look.
"Healthy Aging & Longevity" content track since 2024. 20+ aging biotechs in partnering each year.
Geriatric Oncology Task Force sessions; aging–cancer intersection is increasingly prominent as senescence maps to treatment response.
Longevity company presentations (Altos, BioAge, Insilico, Retro all announce at JPM Week). Longevity Investor Forum satellite co-times.
Dedicated aging/longevity panels annually. Strong consumer-longevity and longevity-tech signal.
Longevity tech + wearables + healthspan consumer devices. AgeTech Collaborative by AARP runs a dedicated CES zone.
"Healthy Longevity Initiative" — WEF's formal working group on demographic aging. Panels and published white papers each January.
Systems Aging (Jun 2026), Stress Granules, Autophagy, Mitochondria & Metabolism, Telomeres — multiple GRCs touch aging each year.
Multiple aging-related Keystone meetings each year: cellular senescence, autophagy, NAD+ metabolism, mitochondrial dysfunction.
A month-by-month skeleton of the flagship meetings. Use the directory above for the full 150+ list — this is just the anchor points.
The year's busiest month — JPM Week dominates.
Clinical ops & genomics peak.
Digital health + European regulatory.
AACR dominates.
Boston biotech month.
BIO + European mega-medicine.
Quieter month — use for focused travel.
Academic chemistry + cardiology.
Peak academic aging month.
The longevity super-month.
BD closeout + big-society peak.
ASH, antibody, ML finales.
No-one attends 150 meetings. Here's how six different roles should prioritize 2026. Each list is 8–10 events; anything else is opportunistic.
Profile: Insilico-type platform company with aging indications.
Profile: Clinical-stage oncology asset holder.
Profile: Needs to meet LPs, VCs, family offices.
Profile: In-licensing scout for mid/large pharma.
Profile: Protein engineering, bispecifics, ADCs.
Profile: Grant-funded aging biology PI.
Every meeting in this directory is scored on five dimensions. The weights shift based on who's asking — which is why the persona shortlists above look different from the alphabetical directory.
| Dimension | Weight | What it measures |
|---|---|---|
| Prestige | 25% | Brand recognition, keynote caliber, peer-review rigor, historical impact. |
| Networking | 25% | Density of senior BD / C-suite / investor access; quality of 1:1 opportunities. |
| Science | 20% | Scientific signal — novel data, embargoed trials, mechanistic depth. |
| AI-DD Relevance | 20% | How well-positioned for AI drug discovery / ML / computational biology speakers and dealflow. |
| Value | 10% | Cost-to-signal ratio (registration + travel vs. deliverables). |
Overall = 0.25·Prestige + 0.25·Networking + 0.20·Science + 0.20·AI-DD + 0.10·Value
All scores reflect May 2026 state-of-the-field judgment. Methodology is reproducible: anyone applying the same five-dimension framework with the same weights should arrive within ±0.3 on any given conference. The star ratings in the directory table are a rounded version of the Prestige axis alone, for quick visual scan.
Life-science conferences cluster in a small number of cities. If you live within easy travel of one of these, you can attend 60–80% of the meetings that matter to you without long-haul flights.
The unofficial biotech capital. Annual hosts: PEGS, ASGCT, Bio-IT World, Discovery on Target, DPHARM, Festival of Biologics USA, Antibody Engineering, BioProcess International, ARDD 2026, Harvard/Glenn, Aging Code Summit, Bispecifics Summit.
Density: 15+ major meetings/year • Peak months: May, Sep–Oct
The finance + AI capital. Annual hosts: JPM Healthcare Week, Biotech Showcase, PMWC, ASCO GI/GU, Festival of Genomics (Boston co-host), Rock Health Summit, BIO Investor Forum, ATS, SALTS, BAAM, BerkeleyCAL, Vitalist Bay, NVIDIA GTC.
Density: 12+ major meetings/year • Peak months: Jan, Feb
West-coast science capital. Annual hosts: SLAS International, DDC, AACR Annual (rotating), PEGS satellites, WORLDSymposium, ACR, ESMO (SD selective), World ADC, CTAD, Antibody Engineering & Therapeutics, RAPS, Molecular Med Tri-Con.
Density: 10+ major meetings/year • Peak months: Jan–Apr
Policy + regulatory science capital. Annual hosts: SITC, NORD Summit, NIH Geroscience, FDA forums, Targeting Metabesity, A4LI DC, Milken Future of Health, AASLD.
Density: 8+ major meetings/year • Peak months: Oct–Nov
Investor capital. Annual hosts: BIO CEO & Investor, Jefferies Healthcare, Cantor Global Healthcare, Piper Sandler Healthcare, and countless buy-side events.
Density: 6+ major meetings/year • Peak months: Feb, Jun, Dec
European investor + clinical-longevity hub. Annual hosts: LSX World Congress, LSX Leaders, AIDD Summit EU, Longevity Med Summit, Festival of Genomics (European edition).
Density: 8+ major meetings/year • Peak months: Apr–Jun
European pharma HQ triangle. Annual hosts: Festival of Biologics Basel, DIA Europe, Sachs Biotech Europe, Sachs CEO Forum, ESMO IO (Geneva), Longevity Investors Conference (Gstaad).
Density: 6+ major meetings/year • Peak months: Mar, Sep–Nov
German science + BD hub. Annual hosts: BIO-Europe Fall, ESMO Munich, World Health Summit (Berlin), EMBL Symposia (Heidelberg), FBLD (Heidelberg).
Density: 5+ major meetings/year • Peak months: Oct–Nov
Northern European longevity + clinical hub. ARDD (Copenhagen, historically), Longevity Summit Dublin, EASL Amsterdam, HLTH Europe Amsterdam, ERS Amsterdam.
Density: 5+ major meetings/year • Peak months: Jun, Sep–Nov
APAC pharma + AI hub. Annual hosts: ChinaBio Partnering, DIA China, CPHI China, AI & Big Data in Pharma Asia.
Density: 4+ major meetings/year • Peak months: May–Sep
Japanese biotech gateway. BIO Japan (Yokohama) anchors the calendar; DIA Japan, JBA Annual, and Japan Pharmaceutical Manufacturers Assoc. events orbit.
Density: 3+ major meetings/year • Peak month: Oct
APAC regional HQ hub. ESMO Asia, Asia BioPharma Licensing, WCLC (rotating), ICAD, Asia-Pacific Longevity Medicine, LIC Asia.
Density: 4+ major meetings/year • Peak months: Oct–Dec
Our editorial read on the directional shifts that matter this year and next. Bookmark and revisit in Dec 2026 to see how they scored.
ARDD's 2026 move from Copenhagen to Harvard Medical School is the single biggest signal in the aging meeting circuit in a decade. Combined with Biomarkers of Aging at MIT and the Glenn Symposium, Boston becomes the de facto longevity-biology capital for calendar 2026.
The proliferation of small "AI in pharma" events from 2021–2024 is reversing. Bio-IT World, AIDD (Hanson Wade), and NVIDIA GTC Healthcare now absorb the bulk of AI-DD attendance, with boutique events folding or pivoting to focused verticals.
Hevolution Global Healthspan Summit (Riyadh) moved from new entrant (2024) to second-most-important translational longevity meeting in 24 months. Saudi PIF capital is crowding Gulf-region programming; expect UAE and Qatar announcements during 2026.
ADA and Targeting Metabesity have absorbed longevity-curious audiences since the tirzepatide/semaglutide aging-adjacent readouts. The boundary between diabetes, obesity, and healthspan meetings is functionally gone; expect unified programming by 2027.
The 2020–2022 surge in virtual-only events is over. What remains is a stable hybrid model: in-person for BD and 1:1s, virtual tails for broad education. ARDD's 10,000+ online tail is the template most aging meetings now follow.
With Sachs Biotech Europe, Festival of Biologics Basel, and a rotating DIA Europe base, Basel is reclaiming the European pharma-BD capital title from Amsterdam and London. The Swiss tax environment and Roche/Novartis gravity anchor the trend.
RAPS Convergence, DIA Global, and FDA/CDER Science Forum are all reporting record attendance as sponsors race to align on accelerated-approval pathways for aging-biology endpoints. Expect a purpose-built Aging Regulatory Science summit by 2027.
We've been tracking life-science conferences since 2007. Here's what readers ask us most.
Dates are verified against official conference websites as of May 2026. Some 2027 dates are projected from multi-year rotation patterns — confirm closer to each event. We revise the database whenever an organizer publishes a correction.
The 13th ARDD (2026) is hosted at Harvard Medical School for the first time — a one-year US edition co-organized with Vadim Gladyshev's group and David Sinclair's lab. The meeting returns to the Copenhagen rotation in 2027. Confirmed via the ARDD organizing committee and agingpharma.org.
For an AI-DD longevity biotech: ARDD (translational science + BD), Bio-IT World (AI/ML in life sciences), JPM Healthcare (capital), AACR (oncology + AI translation), and BIO International (global partnering). Add Hevolution Global Healthspan Summit if Middle East funding is strategic.
We score each meeting on five dimensions — Prestige (25%), Networking (25%), Science (20%), AI-DD Relevance (20%), and Value (10%) — then compute an overall 0-10. Rankings shift by persona: a pure-oncology company, a capital-raising CEO, and a longevity biotech will each weight these differently.
It's comprehensive for the major categories — mega-meetings, AI drug discovery, oncology, longevity, cell & gene therapy, biologics, investor/BD, and APAC. We deliberately exclude purely local society meetings and commercial training courses. If we've missed something that matters, let us know.
No. Biotechnology Meetings has been independently maintained since 2007. We don't accept paid listings and we don't take sponsorship from conference organizers. Editor's picks reflect editorial judgment, not commercial relationships.
Email info@biotechnologymeetings.com with the conference name, dates, venue, organizer, and an authoritative URL. We review submissions weekly.
Eighteen categories are used throughout this directory. Most conferences fit a single primary category — some (like ARDD, BIO International) naturally straddle two or three. The primary assignment reflects where the meeting's center of gravity sits.
The industry's largest and most prestigious meetings by attendance and brand recognition. JPM Healthcare, BIO International, the major society annuals.
Machine learning, generative biology, and computational chemistry applied to pharma R&D. Bio-IT World, AIDD (Hanson Wade), NVIDIA GTC Healthcare.
Cancer research and clinical oncology — AACR, ASCO, ESMO, ASH, SITC, SABCS, tumor-type-specific congresses.
Geroscience, rejuvenation biology, and translational longevity therapeutics. ARDD, GRC Biology of Aging, Hevolution, Longevity Summit Dublin.
Medicinal chemistry, HTS, fragment-based, and target-ID meetings. SLAS, DDC, Discovery on Target, EFMC-ISMC.
Protein engineering, antibodies, bispecifics, ADCs, and biologics manufacturing. PEGS, Festival of Biologics, World ADC.
CGT science, translation, and manufacturing. ASGCT, ISCT, Phacilitate Advanced Therapies Week, Meeting on the Mesa.
Clinical operations, trial design, and execution. DIA Global, SCOPE, DPHARM, SCRS.
FDA, EMA, NMPA, and regulatory-science meetings. RAPS Convergence, DIA Europe, DIA China, FDA/CDER forums.
Specialty clinical societies: cardiology (AHA, ACC, ESC), endocrinology (ADA), hepatology (EASL, AASLD), rheumatology (ACR, EULAR), respiratory (ATS, ERS).
Academic-only research meetings — Gordon Research Conferences, Cold Spring Harbor, Keystone Symposia, EMBO Workshops, FASEB SRCs.
Genomics, diagnostics, and molecular medicine. PMWC, ASHG, AGBT, ESHG, Festival of Genomics.
Healthcare IT, digital therapeutics, telehealth, and consumer health tech. HLTH, HIMSS, ViVE, Rock Health.
Rare disease policy, advocacy, and clinical research. WORLDSymposium, NORD Summit, Global Genes, Rare Disease Day.
Public and private biotech capital markets. Biotech Showcase, BIO CEO, Jefferies, TD Cowen, LSX World Congress, Longevity Investors Conference.
Licensing, partnering, and dealmaking. BIO-Europe, BIO-Europe Spring, ChinaBio Partnering, CPHI, Asia BioPharma Licensing.
Health policy, global health, and advocacy. World Health Summit, WEF, OECD Global Forum, Milken Institute, A4LI DC.
APAC regional flagships. BIO Japan, BIO Korea, BioAsia, BIO Taiwan, AI & Big Data in Pharma Asia, PMAC.